IVVD — Invivyd, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1832038 ·
Last close
$0.51
Market Cap
$151.09M
52W High
$3.01
52W Low
$0.49
ADV30
4,231,067
Next earnings
2026-11-16

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 15,449,000 14,406,000 -34,679,000 -33,468,000 183,905,000 126,398,000 33,422,000
Jun 2026 14,285,000 13,012,000 -45,820,000 -44,393,000 218,883,000 160,080,000 37,803,000
Mar 2026 13,744,000 12,712,000 -43,136,000 -41,400,000 241,742,000 184,153,000 38,692,000
Dec 2025 17,207,000 16,067,000 -12,555,000 -11,070,000 276,883,000 226,689,000 35,343,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-108,422,000
Investing CF
$-1,236,000
Financing CF
$234,833,000
CapEx
$-1,391,000
Dividends Paid
—
Buybacks
$-231,000
EPS Diluted TTM
$-0.45
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,040,276,000
Inventory
$310,000
Receivables
$11,683,000
ST Investments
—
EBIT TTM
$-112,534,000
Pretax Income TTM
$-107,333,000
Interest Exp TTM
—
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$58,365,000
EBITDA
$-111,888,000
Free Cash Flow
$-69,950,752
Enterprise Value
$79,843,992
Total Cash
$160,080,000
Total Debt
$8,391,000
Shares Out
294,758,746
Trailing EPS
$-0.31
Book Value
$0.61
ROE
-95.9%
ROA
-45.7%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 53,426,000 -55,560,000 -52,489,000 276,883,000 35,343,000 241,540,000 -58,135,000
Dec 2024 25,384,000 -176,876,000 -169,925,000 129,515,000 61,976,000 67,539,000 -170,491,000
Dec 2023 0 -207,783,000 -198,643,000 229,181,000 51,713,000 177,468,000 -173,164,000
Dec 2022 0 -226,258,000 -241,317,000 383,167,000 27,197,000 355,970,000 -219,987,000

TTM Snapshot

Revenues TTM
$58,365,000
NetIncome TTM
$-107,333,000
OpCashFlow TTM
—
Assets (Latest)
$218,883,000
Forward EPS
$-0.55

Max Pain — expiry 2026-12-18

max pain strike: $0.50 · spot: $0.47 · call oi: 3,552 · put oi: 886
Expected Move to 2026-12-18: ±$0.16 (32.91%) — implied range $0.32 – $0.63 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IPHA Innate Pharma SA $148.56M $1.33 —
STRO SUTRO BIOPHARMA, INC. $148.08M $8.92 —
HUMA Humacyte, Inc. $139.18M $0.50 —
TARA Protara Therapeutics, Inc. $137.10M $2.32 —
IPHYF Innate Pharma SA $168.56M $1.51 —

News headlines (Yahoo Finance, 1h cache)

Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
2026-11-16 12:15 · Yahoo
Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-16 12:01 · Yahoo
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-03 12:01 · Yahoo
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
2026-10-21 11:01 · Yahoo
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
2026-10-14 11:01 · Yahoo
Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
2026-10-05 02:02 · Yahoo
Invivyd’s Covid-directed mAb hits Phase III safety goals
2026-09-30 16:19 · Yahoo
Invivyd Reports Positive Phase 3 LIBERTY Results for VYD2311 and Plans Accelerated Approval Submission
2026-09-29 14:40 · Yahoo
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for V
2026-09-29 11:01 · Yahoo
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
2026-09-13 14:50 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.